RealFeedApp Measuring buoyant mass of T cells predicts response to immunotherapy more accurately than tumor mutational burden
MIT researchers demonstrated that measuring the buoyant mass of T cells predicts patient response to immune checkpoint blockade more accurately than tumor mutational burden.
- Field
- genetics and genomes
- What they did
- Researchers from MIT measured the buoyant mass of T cells and demonstrated that this method predicts patient response to immune checkpoint blockade therapy more accurately than traditional tumor mutational burden analysis.
- Why it matters
- This technique can improve the prediction of cancer cell sensitivity to treatment and enhance the productivity of cell cultures used in gene therapy manufacturing.
#t cells#immunotherapy#mit#buoyant mass#smr technology
